Algernon Doses 1st Patient in Phase 2 Chronic Cough Trial

Clinical stage pharmaceutical development Company Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: BTHCF, Forum) reported on Wednesday that the first patient had been dosed in its Phase 2 idiopathic pulmonary fibrosis (IPF) and chronic cough clinical study of its re-purposed drug NP-120 (Ifenprodil). The patient was enrolled and dosed at the Waikato Hospital located in Hampton, New Zealand. The drug Ifenprodil has been shown to - “mediate anti-inflammatory responses and reduce pulmonary fibrosis in a murine model of IPF."

To learn more about this trial and Phase 2, click here.

The Company added that since closing its financing on May 13th, 2020, it had issued 5.3 million common shares, for net proceeds to the Company of $636,000.




FULL DISCLOSURE: Algernon Pharmaceuticals Inc. is a client of Stockhouse Publishing.